In IDAC consolidation group (25 AML patients), 2, 8 and 2 patients had FLT3-ITD, NPM1 and CEBPA mutation, respectively and 13 patients had no gene mutation. The gene discussed is FLT3; the disease is acute myeloid leukemia.